within Pharmacolibrary.Drugs.ATC.J;

model J01DI01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018699999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00959,
    k12             = 8.32,
    k21             = 8.32
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DI01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftobiprole medocaril is a cephalosporin antibiotic prodrug that is rapidly converted in vivo to its active form, ceftobiprole. It is used for the treatment of hospital-acquired and community-acquired pneumonia and has activity against a wide spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved in several countries in Europe and elsewhere, but not currently approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects, with values based on a population pharmacokinetic analysis after intravenous infusion.</p><h4>References</h4><ol><li><p>Azanza Perea, JR, &amp; Sádaba Díaz de Rada, B (2019). Ceftobiprole: pharmacokinetics and PK/PD profile. <i>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</i> 32 Suppl 3(Suppl 3) 11–16. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31364336/\">https://pubmed.ncbi.nlm.nih.gov/31364336</a></p></li><li><p>Scheeren, TW (2015). Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia. <i>Future microbiology</i> 10(12) 1913–1928. DOI:<a href=\"https://doi.org/10.2217/fmb.15.115\">10.2217/fmb.15.115</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26573022/\">https://pubmed.ncbi.nlm.nih.gov/26573022</a></p></li><li><p>Torres, A, et al., &amp; Pea, F (2016). Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical pharmacokinetics</i> 55(12) 1507–1520. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0418-z\">10.1007/s40262-016-0418-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27272266/\">https://pubmed.ncbi.nlm.nih.gov/27272266</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DI01;
